Jaguar Health Reports Second Quarter 2026 Financials Back to the Newsroom Jaguar Health Reports Second Quarter 2026 Financials Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight ...